S1203
|
SWOG
|
A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
S1207
|
SWOG
|
Phase III Randomized; Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study - evaluating everolimus with endocrine therapy
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1216
|
SWOG
|
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1300
|
SWOG
|
A Randomized; Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients Who Have Progressed Systematically After Previous Clinical Benefit From Crizotinib Monotherapy<br>
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
S1314
|
SWOG
|
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized; Muscle-Invasive Bladder Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1318
|
SWOG
|
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone; Vincristine; Methotrexate; 6-Mercaptopurine) for Patients >= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517); Prednisone and Blinatumomab for Patients >= 65 Years Of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL; and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dastainib-Sensitive Mutations or Kinase Fusions (DSMKF)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
S1320
|
SWOG
|
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
S1400
|
SWOG
|
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1403
|
SWOG
|
A Randomized Phase II Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S1404
|
SWOG
|
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|